Business Context and Reporting Period
Daré Bioscience, Inc. (DARE) filed a Form 8-K Current Report on April 10, 2026, regarding the completion of a previously announced Regulation A offering. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
The filing details the closing of an equity offering rather than standard operating financial results. Key transaction metrics include:
- Offering Type: Regulation A offering of Investor Units.
- Units Issued: 3,470 Investor Units (out of a maximum of 4,854,000 authorized).
- Components per Unit: One share of Series A Convertible Preferred Stock and two warrants to purchase one share of common stock each.
- Offering Price: $5.00 per Investor Unit.
- Total Gross Proceeds: $17,350 (3,470 units x $5.00).
- Warrants Issued: 6,940 Investor Warrants.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
Material Changes
The primary material change is the issuance of 3,470 shares of Series A Convertible Preferred Stock and the associated warrants, increasing the company's capital structure. This represents the initial closing of the offering authorized under the Form 1-A offering statement qualified by the SEC on April 1, 2026.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on operational outlook, or a discussion of risks and contingencies beyond the standard incorporation by reference to the offering circular and a prior Form 8-K filed on January 29, 2026, for details on conversion and exercise terms.
Investor Verification Checklist
- Verify the total number of Investor Units sold in subsequent closings, as this filing only covers the initial 3,470 units.
- Review the offering circular supplement dated March 26, 2026, for specific terms regarding the conversion of Series A Preferred Stock and exercise of warrants.
- Confirm the use of proceeds from the $17,350 raised in this specific closing.
- Check for any underwriting discounts or commissions that may reduce the net proceeds from the gross offering price.